Friday, April 20, 2007 9:19:09 AM
[Good news for TEVA - Sandoz is out from the generic Biaxin market which is about $250M]
http://biotech.seekingalpha.com/article/32912?source=d_email&u=6464
Posted on Apr 20th, 2007 with stocks: ABT
Aaron F. Barkoff submits: This past Monday, Judge David H. Coar of the U.S. District Court for the Northern District of Illinois granted Abbott's (ABT) motion for a preliminary injunction to stop Sandoz [a Novartis Pharmaceuticals (NVS) subsidiary] from selling a generic version of Biaxin XL (clarithromycin extended release tablets).
Abbott earns about $300 million each year in the U.S. from sales of Biaxin XL, an antibiotic used primarily for the treatment of bacterial infections of the skin and upper respiratory system.
The preliminary injunction against Sandoz is a reversal of fortune for Abbott, considering that last December Judge Coar denied Abbott's motion for a temporary restraining order. Now, in a 61-page opinion (pdf file), Judge Coar explained that "after having the benefit of a full hearing, this Court is able to better decide the merits of enjoining Sandoz from further selling or marketing its extended release formulation of clarithromycin."
Abbott alleged that Sandoz's generic version of Biaxin XL infringes U.S. Patent Nos. 6,010,718 and 6,551,616, which claim extended release formulations of clarithromycin. Judge Coar found that Abbott demonstrated "a substantial likelihood of proving Sandoz's product infringes upon claims 1 and 4 of the '718 patent." Moreover, he found that Sandoz's obviousness and inequitable conduct defenses lack substantial merit.
With regard to inequitable conduct, Judge Coar wrote that although Sandoz showed a substantial likelihood of proving materiality and intent to deceive with respect to the '616 patent, Abbott abandoned the '616 patent claim in question on its own volition and "it seems wholly inequitable to hold a patent invalid for fraudulent conduct in the prosecution of a claim that was withdrawn before actual prosecution had even begun." Judge Coar further observed that "[r]edemption is one of the core principles of the American ethos."
Besides Sandoz, Abbott is fending off generic competition to Biaxin XL from Andrx, Ranbaxy, Roxane, and Teva (TEVA). In January, the Federal Circuit affirmed a preliminary injunction against Andrx. Last August, Abbott and Teva settled their litigation, although on Tuesday Teva filed a complaint (pdf file) in the Southern District of New York to enforce the settlement.
Recent TEVA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 12:03:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 12:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:41:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:38:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:27:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:23:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:20:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:17:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:14:54 AM
- Adobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and More • IH Market News • 06/14/2024 11:21:47 AM
- Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/04/2024 08:05:00 PM
- New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) • Business Wire • 06/01/2024 06:25:00 PM
- Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 • Business Wire • 06/01/2024 06:20:00 PM
- Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) • Business Wire • 05/29/2024 10:38:00 PM
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. • Business Wire • 05/21/2024 12:25:00 AM
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. • GlobeNewswire Inc. • 05/21/2024 12:25:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 12:36:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:30:32 PM
- Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations • Business Wire • 05/15/2024 12:15:00 PM
- Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News • IH Market News • 05/09/2024 11:53:19 AM
- Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook • Business Wire • 05/08/2024 11:00:00 AM
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia • Business Wire • 05/08/2024 10:30:00 AM
- Teva to Present at the 2024 Bank of America Healthcare Conference • Business Wire • 05/02/2024 10:30:00 PM
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets • Business Wire • 05/02/2024 12:30:00 PM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM